Presentation

0 Comments

29 December 2016

Making Sense of Anti-thrombotic Therapy Pre-PCI

Previous | Next
Download

Dan Blackman

Dan Blackman, of Leeds General Infirmary, discusses the use of anti-thrombotic therapy prior to PCI. The upfront use of Low Molecular Weight Heparin or Fondaparinux in the OASIS 5 trial is discussed. Also reviewed is the use of glycoprotein IIb/IIIa inhibitors during PCI.

Download

Dan Blackman

Dan Blackman, of Leeds General Infirmary, discusses the use of anti-thrombotic therapy prior to PCI. The upfront use of Low Molecular Weight Heparin or Fondaparinux in the OASIS 5 trial is discussed. Also reviewed is the use of glycoprotein IIb/IIIa inhibitors during PCI.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In